Abstract: A method of updating of firmware to a client device such as a BLE button is provided. The method includes the steps of providing a first user device and detecting the client device with the first user device. It is determined if the client device is in an update mode in response to instructions from a second user device. The firmware is uploaded from the first user device to the client device in response to the client device being in the update mode.

Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: Disclosed herein are compounds of Formula I and methods for making the same: Also described herein are the use of such compounds, compositions for the treatment of diseases and disorders that are mediated, at least in part, by one or more cyclins, including cancer, and intermediates useful in the preparation of these compounds.

Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Abstract: An electronic monitoring system and a method of dynamically altering an activity zone within the electronic monitoring system are provided. The electronic monitoring system includes a camera having a first field-of-view and operating to generate a first image data. A user device is configured to receive the first image data; define an activity zone at a first area within the first image data; define a triggering event; and define an object in the first field-of-view. A computer-readable memory stores the data corresponding to the object. An electronic processor executes a stored program and receives the image data from the camera to generate an alert in response to the occurrence of a triggering event.

Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist.

Abstract: A method of dynamically altering an activity zone within an electronic monitoring system is provided. The method includes generating first image data with a camera having a first field-of-view. Upon receiving the first image data, defining an activity zone therein. Subsequently, generating a second image data with the camera having a second field-of view that differs at least in-part from the first field-of-view. In response to the second image data being different from the first image data, modifying the activity zone to be at a second area that corresponds to the area defined in the first image data, and then responding to a triggering event occurring within the activity zone of the second area. The invention additionally relates to a system that implements such a method.

Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

Abstract: An electronic monitoring system has one or more imaging devices that can detect at least one triggering event comprising sound and motion and a controller that executes a program to categorize the triggering event as being located in a user-defined activity zone within the field of view and/or as being a taxonomic-based triggering event. Upon categorizing the triggering event, the system generates an output comprising a video component and an audio component. At least a portion of the audio component is modified if the triggering event is a categorized triggering event. Modification of the audio may include muting all or a portion of the audio component of the output.

Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.

Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.

Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.

Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Compounds are provided as chemokine inhibitors having the structure:

Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.